CoChat
Sign Up
Cited by 16

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Reprogramming the pancreatic cancer stroma and immune landscape by a silicasome nanocarrier delivering nintedanib, a protein tyrosine kinase inhibitor

Luo, Lijia, Wang, Xiang, Liao, Yu-Pei, Xu, Xiao, Chang, Chong Hyun, Nel, Andre E.·2024·Nano Today
DOI 10.1016/j.nantod.2023.102058
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nantod.2023.102058

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 42

  1. Siegel, 2023, Cancer statistics, 2023, CA Cancer J. Clin., 73, 17
  2. Erkan, 2012, The role of stroma in pancreatic cancer: diagnostic and therapeutic implications, Nat. Rev. Gastroenterol. Hepatol., 9, 454, 10.1038/nrgastro.2012.115 · DOI · Paper page
  3. Meng, 2018, Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer, Adv. Drug Deliv. Rev., 130, 50, 10.1016/j.addr.2018.06.014 · DOI
  4. Liu, 2022, Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies, Theranostics, 12, 1030, 10.7150/thno.64805 · DOI
  5. Ortíz, 2021, Nanomedicine to overcome multidrug resistance mechanisms in colon and pancreatic cancer: recent progress, Cancers, 13, 2058, 10.3390/cancers13092058 · DOI
  6. Nel, 2022, Multifunctional lipid bilayer nanocarriers for cancer immunotherapy in heterogeneous tumor microenvironments, combining immunogenic cell death stimuli with immune modulatory drugs, ACS Nano, 16, 5184, 10.1021/acsnano.2c01252 · DOI
  7. Frampton, 2020, Liposomal irinotecan: a review in metastatic pancreatic adenocarcinoma, Drugs, 80, 1007, 10.1007/s40265-020-01336-6 · DOI
  8. Von Hoff, 2013, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine, N. Engl. J. Med, 369, 1691, 10.1056/NEJMoa1304369 · DOI · Paper page
  9. Liu, 2017, Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer, J. Clin. Invest, 127, 2007, 10.1172/JCI92284 · DOI
  10. Liu, 2016, Irinotecan delivery by lipid-coated mesoporous silica nanoparticles shows improved efficacy and safety over liposomes for pancreatic cancer, ACS Nano, 10, 2702, 10.1021/acsnano.5b07781 · DOI
  11. Liu, 2019, Improved efficacy and reduced toxicity using a custom-designed irinotecan-delivering silicasome for orthotopic colon cancer, ACS Nano, 13, 38, 10.1021/acsnano.8b06164 · DOI
  12. Liu, 2021, Combination chemo-immunotherapy for pancreatic cancer using the immunogenic effects of an irinotecan silicasome nanocarrier plus Anti-PD-1, Adv. Sci., 8
  13. Luo, 2022, Nanocarrier Co-formulation for Delivery of a TLR7 Agonist plus an Immunogenic Cell Death Stimulus Triggers Effective Pancreatic Cancer Chemo-immunotherapy, ACS Nano, 10.1021/acsnano.2c06300 · DOI
  14. Lakkakula, 2019, Small molecule tyrosine kinase inhibitors and pancreatic cancer—Trials and troubles, Semi. Cancer Bio, 56, 149, 10.1016/j.semcancer.2018.09.011 · DOI
  15. Fujimoto, 1998, Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis, Eur. J. Cancer, 34, 1439, 10.1016/S0959-8049(98)00069-0 · DOI
  16. Ohta, 1995, Expression of basic fibroblast growth factor and its receptor in human pancreatic carcinomas, Br. J. Cancer, 72, 824, 10.1038/bjc.1995.420 · DOI
  17. Hilberg, 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy, Cancer Res, 68, 4774, 10.1158/0008-5472.CAN-07-6307 · DOI · Paper page
  18. Fala, 2015, Ofev (Nintedanib): first tyrosine kinase inhibitor approved for the treatment of patients with idiopathic pulmonary fibrosis, Am. Health Drug Benefits, 8, 101
  19. Tu, 2022, Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells, Theranostics, 12, 747, 10.7150/thno.65828 · DOI
  20. Wind, 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib, Clin. Pharmacokinet., 58, 1131, 10.1007/s40262-019-00766-0 · DOI
  21. Allen, 2021, Immune checkpoint inhibition in syngeneic mouse cancer models by a silicasome nanocarrier delivering a GSK3 inhibitor, Biomaterials, 269, 10.1016/j.biomaterials.2020.120635 · DOI
  22. Hibi, 2016, FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib, Cancer Sci., 107, 1667, 10.1111/cas.13071 · DOI
  23. Jain, 2005, Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy, Science, 307, 58, 10.1126/science.1104819 · DOI · Paper page
  24. Kato, 2021, Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts, Br. J. Cancer, 124, 914, 10.1038/s41416-020-01201-z · DOI
  25. Wang, 2018, Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion, Front. Pharm., 9
  26. Wu, 2019, PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition, Front. Immunol., 10, 10.3389/fimmu.2019.02022 · DOI
  27. Yi, 2021, Regulation of PD-L1 expression in the tumor microenvironment, J. Hematol. Oncol., 14, 10, 10.1186/s13045-020-01027-5 · DOI · Paper page
  28. Awasthi, 2015, Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer, Cancer Lett., 358, 59, 10.1016/j.canlet.2014.12.027 · DOI
  29. Li, 2020, Overcoming therapeutic failure in osteosarcoma via Apatinib-encapsulated hydrophobic poly(ester amide) nanoparticles, Biomater. Sci., 8, 5888, 10.1039/D0BM01296C · DOI · Paper page
  30. Lu, 2019, Afatinib-loaded immunoliposomes functionalized with cetuximab: A novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer, Int. J. Pharm., 560, 126, 10.1016/j.ijpharm.2019.02.001 · DOI
  31. Gao, 2019, Preparation and evaluation of folate-decorated human serum albumin nanoparticles for the targeted delivery of sorafenib to enhance antihepatocarcinoma efficacy, J. Drug Deliv. Sci. Technol., 54
  32. Blair, 2019, Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer, Clin. Cancer Res, 25, 5351, 10.1158/1078-0432.CCR-18-4192 · DOI
  33. Zinger, 2019, Collagenase nanoparticles enhance the penetration of drugs into pancreatic tumors, ACS Nano, 13, 11008, 10.1021/acsnano.9b02395 · DOI
  34. Peng, 2022, Local release of TGF-β inhibitor modulates tumor-associated neutrophils and enhances pancreatic cancer response to combined irreversible electroporation and immunotherapy, Adv. Sci., 9, 10.1002/advs.202105240 · DOI
  35. Massó-Vallés, 2015, Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma, Cancer Res, 75, 1675, 10.1158/0008-5472.CAN-14-2852 · DOI
  36. Jain, 2001, Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy, Nat. Med., 7, 987, 10.1038/nm0901-987 · DOI · Paper page
  37. Carmeliet, 2011, Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases, Nat. Rev. Drug Discov., 10, 417, 10.1038/nrd3455 · DOI
  38. Hosein, 2020, Pancreatic cancer stroma: an update on therapeutic targeting strategies, Nat. Rev. Gastroenterol. Hepatol., 17, 487, 10.1038/s41575-020-0300-1 · DOI · Paper page
  39. Huang, 2012, Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy, Proc. Natl. Acad. Sci., 109, 17561, 10.1073/pnas.1215397109 · DOI · Paper page
  40. Batchelor, 2013, Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation, Proc. Natil. Acad. Sci., 110, 19059, 10.1073/pnas.1318022110 · DOI
  41. Matsumoto, 2011, Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia, Cancer Res, 71, 6350, 10.1158/0008-5472.CAN-11-2025 · DOI
  42. Tsukita, 2019, Beneficial effects of sunitinib on tumor microenvironment and immunotherapy targeting death receptor5, OncoImmunology, 8, 10.1080/2162402X.2018.1543526 · DOI

Cited by

Sorted by citations

See all 16

Metadata

Authors
Luo, L., Wang, X., Liao, Y.-P., Xu, X., Chang, C. H., & Nel, A. E.
Venue
Nano Today
Publisher
Elsevier BV
Published
2024-02
Volume
54
Pages
102058
ISSN
1748-0132
DOI
10.1016/j.nantod.2023.102058
Cited by
16
References
6
Language
en
Licence
Funders
  • U.S. Public Health Service (R01CA247666–03)
  • California NanoSystems Institute
  • National Cancer Institute
  • University of California, Los Angeles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reprogramming the pancreatic cancer stroma and immune landscape by a silicasome nanocarrier delivering nintedanib, a protein tyrosine kinase inhibitor. https://app.cochat.ai/papers/10.1016/j.nantod.2023.102058
The paper
Luo, L., Wang, X., Liao, Y.-P., Xu, X., Chang, C. H., & Nel, A. E. (2024). Reprogramming the pancreatic cancer stroma and immune landscape by a silicasome nanocarrier delivering nintedanib, a protein tyrosine kinase inhibitor. Nano Today. https://doi.org/10.1016/j.nantod.2023.102058